No Data
Overview of the restrictions and unlocks of A-shares on March 12.
According to the Zhito Finance APP, on March 12, a total of 1 listed company had its restricted shares unlocked, with a total market value of approximately 61.9667 million yuan. The specific conditions for the restricted share unlock today are as follows: Stock Name Stock Code Share Type Unlocked Share Quantity Harbin Gloria Pharmaceuticals 002437 Stock-based Incentive Restricted Circulation 28.9564 million.
Difficult to recover equity transfer funds. Harbin Gloria Pharmaceuticals' PD-1 "divestiture" lawsuit may face a second instance | Quick Reading of Announcement.
① After winning the first instance, Harbin Gloria Pharmaceuticals has further developments in the lawsuit regarding the separation of Innovative Drugs assets. ② The acquiring party, Puxing Puli, has filed an appeal, requesting a ruling that it is not required to pay any penalties to Harbin Gloria Pharmaceuticals.
Here's Why HARBIN GLORIA PHARMACEUTICALS (SZSE:002437) Can Manage Its Debt Responsibly
Yuheng Pharmaceutical: 2024 Annual Performance Forecast
Benign Growth For HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Underpins Its Share Price
Harbin Gloria Pharmaceuticals (002437.SZ): Currently, there are no plans for a spin-off listing on the Hong Kong stock market.
On December 19, Gelonghui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated on the investor interaction platform that the company's products, Annao Pills/Tablets, are unique essential pharmaceutical varieties of Traditional Chinese Medicine. The company will increase investment to enhance product competitiveness through improving product qualifications, increasing clinical medication guidelines, and professional academic promotions. Additionally, the company will actively seek differentiated products through independent research and development, cooperative development, mergers and acquisitions, and introduction, continuously enriching the company's product pipeline with high-end generic drugs and distinctive Chinese Patent Medicines, which have technical barriers. The company currently has no plans for a separate listing on the Hong Kong Stock Exchange.
The Market Doesn't Like What It Sees From HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Revenues Yet As Shares Tumble 27%
